

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

01 Jun 2026

### Evaluation of continuous infusion of Nitroglycerin and Dobutamine on incidence and severity of Occult Hypoperfusion in Orthopedic Surgery's Patients who underwent General and Epidural Anesthesia

#### Protocol summary

##### Summary

Tissue Hypoperfusion is a condition of imbalance between oxygen delivery and consumption. It leads to tissue damage if persists, particularly in critically ill patients or during long surgeries. It is important to prevent vasoconstriction of microvessels precluding tissue hypoperfusion and injury. Objectives: This study aims to evaluate the effects of low-dose continuous vasodilator agents on patients susceptible to hypoperfusion damage. Design: This is a double-blind randomized controlled study of 56 patients undergoing long orthopedic surgery (more than 120 minutes). The patients divide randomly into two groups of 28 patients (receivers of nitroglycerin - dobutamine and control); each group also randomizes to receive general and epidural anesthesia in two groups of 14 patients. Inclusion criteria: Patient's satisfaction with participating in the study; Patients in group I and II ASA Score; No history of Liver or Renal insufficiency, DM, HTN, Heart and Pulmonary disease; No acid-base disorders; No TNG, dobutamine or anesthetic drugs allergy; No emergent surgery; No pregnancy; No contraindications of TNG (Idiopathic hypertrophic subaortic stenosis, post myocardial infarction hypertension); No contraindications of dobutamine (myocardial infarction, open angle glaucoma, allergy to phosphodiesterase inhibitors, cerebral hemorrhage, ICP rise, severe anemia, orthostatic hypotension, sildenafil use in restrictive cardiomyopathy) Exclusion Criteria: Resistant drop in blood pressure with mean arterial pressure less than 60; Increasing blood pressure needing therapeutic interventions more than predicted in study method. Setting and conduct: Treatments in intervention group includes trinitroglycerin 0.1 µg/kg/min and dobutamine 1.5-2 µg/kg/min during surgery. The control group receives standard anesthetic and analgesic techniques beside 100 cc normal saline as placebo. All the patients in operation room are under monitoring,

NIBP, IBP, pulse oxymetry and pulse rate measuring. Arterial Blood Gas is checked in the start of anesthesia, per hour during surgery and at the end. Finally data is gathered and analyzed in SPSS and hypoperfusion markers such as pH, bicarbonate, base excess, pO<sub>2</sub>, pCO<sub>2</sub> and oxygen saturation are compared in the groups.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2015011815774N2**

Registration date: **2015-04-04, 1394/01/15**

Registration timing: **retrospective**

Last update:

Update count: **0**

##### Registration date

2015-04-04, 1394/01/15

##### Registrant information

###### Name

Mohammad Mahdi Zamani

###### Name of organization / entity

Tehran University of Medical Sciences, Students' Scientific Research Center

###### Country

Iran (Islamic Republic of)

###### Phone

+98 21 8898 9162

###### Email address

hin@tums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Vice chancellor for research, Iran university of medical sciences

**Expected recruitment start date**

2013-01-01, 1391/10/12

**Expected recruitment end date**

2015-01-01, 1393/10/11

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Evaluation of continuous infusion of Nitroglycerin and Dobutamine on incidence and severity of Occult Hypoperfusion in Orthopedic Surgery's Patients who underwent General and Epidural Anesthesia

**Public title**

The Effect of Continuous Infusion of Nitroglycerin and dobutamine on occult hypoperfusion in patients under anesthesia

**Purpose**

Treatment

**Inclusion/Exclusion criteria**

inclusion criteria : Patient's satisfaction with participating in the study; Patients with group I and II ASA Score; No history of Liver or Renal insufficiency, DM, HTN, Heart and Pulmonary disease; No acid-base disorders; No TNG, dubotamine or anesthetic drugs allergy; No emergent surgery; No pregnancy; No contraindications of TNG(I idiopathic hypertrophic subaortic stenosis, post myocardial infarction hypertension); No contraindications of dubotamine( myocardial infarction, open angle glaucoma, allergy to phosphodiesterase inhibitors, cerebral hemorrhage, ICP rise, severe anemia, orthostatic hypotention, sildenafil use in restrictive cardiomyopathy). Exclusion Criteria: Resistant drop in blood pressure with mean arterial pressure less than 60; Increasing blood pressure needing therapeutic interventions more than predicted in study method.

**Age**

From **18 years** old to **55 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **56**

**Randomization (investigator's opinion)**

Randomized

**Randomization description****Blinding (investigator's opinion)**

Double blinded

**Blinding description****Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics Committee of Iran University of Medical Sciences

**Street address**

West Hemmat Highway

**City**

Tehran

**Postal code****Approval date**

2014-10-18, 1393/07/26

**Ethics committee reference number**

93/105/3332/3

**Health conditions studied****1****Description of health condition studied**

metabolic acidosis

**ICD-10 code**

E87.2

**ICD-10 code description**

An abnormal increase in the acidity of the body's fluids

**Primary outcomes****1****Description**

serum bicarbonate concentration

**Timepoint**

Before start of anesthesia, per hour during surgery, at the end of surgery

**Method of measurement**

Arterial Blood Gas Analysis

**2****Description**

serum base deficit

**Timepoint**

Before start of anesthesia, per hour during surgery, at the end of surgery

**Method of measurement**

Arterial Blood Gas Analysis

**Secondary outcomes**

empty

**Intervention groups**

## 1

### Description

Treatments in intervention group included trinitroglycerin 0.1 µg/kg/min and dobutamine 1.5-2 µg/kg/min during surgery

### Category

Treatment - Drugs

## 2

### Description

The control group received 100 cc normal saline as placebo during the surgery

### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Firoozgar Hospital

##### Full name of responsible person

Dr Mohammad Mahdi Zamani

##### Street address

Operation room, Firoozgar Hospital, Beh Afarin St., Karim Khan Zand Ave., Tehran, Iran

##### City

Tehran

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Vice chancellor for research, Iran university of medical sciences

##### Full name of responsible person

Dr.Morteza Naserbakht

##### Street address

floor 5, central building, junction of Shahid Hemmat & Shahid Chamran Expressways, Tehran

##### City

Tehran

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Vice chancellor for research, Iran university of medical sciences

#### Proportion provided by this source

100

#### Public or private sector

empty

#### Domestic or foreign origin

empty

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

empty

## Person responsible for general inquiries

### Contact

## Person responsible for scientific inquiries

### Contact

#### Name of organization / entity

Department of Anesthesiology, Iran University of Medical Sciences, Tehran, Iran

#### Full name of responsible person

Dr. Saeed Reza Entezari

#### Position

Assistant Professor/Attending Physician

#### Other areas of specialty/work

#### Street address

Rasoul-e-Akram Hospital, niyayesh st., sattarkhan st., Tehran, Iran

#### City

Tehran

#### Postal code

#### Phone

+98 21 6650 9059

#### Fax

+98 218894266

#### Email

sr.entezary@yahoo.com

#### Web page address

## Person responsible for updating data

### Contact

## Sharing plan

#### Deidentified Individual Participant Data Set (IPD)

empty

#### Study Protocol

empty

#### Statistical Analysis Plan

empty

#### Informed Consent Form

empty

#### Clinical Study Report

empty

#### Analytic Code

empty

#### Data Dictionary

empty